Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 105

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Lung adenocarcinoma

Not recruiting

Study Comparing Atezolizumab and Drug Combination with Pembrolizumab and Drug Combination for Patients with Advanced Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

COVID-19

Not recruiting

Study on the Effectiveness and Safety of Bemnifosbuvir for High-Risk COVID-19 Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Atea Pharmaceuticals Inc.

Neoplasm+1

Not recruiting

Study of BMS-986442 and Nivolumab, Alone or with Chemotherapy, for Patients with Advanced Solid Tumors and Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986442
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pneumonia

Not recruiting

Study on the Effectiveness of Co-Trimoxazole for Treating Ventilator-Associated Pneumonia in ICU Patients Compared to a Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer

Not recruiting

Study Comparing Chemotherapy with Nivolumab to Chemotherapy Alone for Patients with Resectable Non-small Cell Lung Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Lung squamous cell carcinoma stage III+1

Not recruiting

Study on the Effect of Ivonescimab, Pemetrexed, and Carboplatin in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutation After Previous Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Oropharyngeal cancer

Not recruiting

Study on Swallowing and Quality of Life in Advanced Head and Neck Cancer Patients Using Cisplatin and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Barium Sulfate
  • Sponsor:Institut Jules Bordet

Non-small cell lung cancer+1

Not recruiting

Study on the Effectiveness and Safety of UV1 Vaccine with or without Sargramostim for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alrefimotide
  • Sponsor:Vestre Viken HF

Pulmonary arterial hypertension

Not recruiting

Study to Determine Safe Doses of Selexipag for Children with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Selexipag
  • Sponsor:Actelion Pharmaceuticals Ltd.

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Secukinumab for Treating Chronic Rhinosinusitis with Nasal Polyps in Non-Type 2 Patients

Registered drugNo placebo
Countries:EstoniaEstonia
  • Participants:18–64 years
  • Substances:Secukinumab
  • Sponsor:Tartu University Hospital

Pulmonary arterial hypertension

Not recruiting

Study on the Safety and Effects of Riociguat for Children Aged 6 to 17 with Pulmonary Arterial Hypertension

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Riociguat
  • Sponsor:Bayer AG

Small cell lung cancer

Not recruiting

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.